Showing 7301-7310 of 8827 results for "".
- Crown’s Patented Xycrobe Technology Supports a Healthy Skin Microbiomehttps://practicaldermatology.com/news/crowns-patented-xycrobe-technology-supports-a-healthy-skin-microbiome/2461440/Crown Aesthetics’ BIOJUVE regimen, which incorporates the patented Xycrobe technology, supports a healthy skin environment, promotes increased skin hydration, decreases redness, regulates sebum production and reduces the appearance of signs of aging such as fine lines and photodam
- Laser Could Prevent UV Radiation-Induced Damage to Skinhttps://practicaldermatology.com/news/laser-could-prevent-uv-radiation-induced-damage-to-skin/2461438/Incidence rates of squamous cell carcinomas (SCCs) are increasing, particularly in high-risk populations, including fair-skinned or immunosuppressed individuals. Few therapeutic options exist to prevent sunlight-induced skin cancer despite rising incidence rates. A recent study determined that ab
- Case Study: Ulcer at Corner of Mouth May Be First Sign of Monkeypox Virushttps://practicaldermatology.com/news/case-study-ulcer-at-corner-of-mouth-may-be-first-sign-of-monkeypox-virus/2461429/Recent infection with monkeypox virus may initially present with an ulcer at the corner of the mouth, according to a case study of a 51-year-old HIV-positive patient published in Deutsches Ärzteblatt international</
- USPTO Grants Patents to TOOsonix A/S for HIFU Technologies in Dermatologyhttps://practicaldermatology.com/news/uspto-grants-patents-to-toosonix-as-for-hifu-technologies-in-dermatology/2461420/The United States Patent and Trademark Office (USPTO) granted TOOsonix A/S patents regarding its key high-intensity focused ultrasound (HIFU) technologies for dermatology The U.S. patent and already granted patents in Europe and China to complete the first phase of securing intellectual prop
- Meet Crown’s ProGen PRP Eclipsehttps://practicaldermatology.com/news/meet-crowns-progen-prp-eclipse/2461417/Crown Aesthetics completed the rebranding of ProGen PRP Advantage, now renamed ProGen PRP Eclipse. ProGen PRP Eclipse is a one-spin system that features 15 mL and 30 mL tubes, yielding 7-15 mL of Platelet Rich Plasma. "Crown's commitment to best-in-class service
- Hydrafacial and Glytone Team Up to Launch New Boosterhttps://practicaldermatology.com/news/hydrafacial-and-glytone-team-up-to-launch-new-booster/2461414/The Beauty Health Company’s Hydrafacial is rolling out a new exfoliating booster co-created with Glytone. The Glytone AHA Resurfacing Cellular Booster leverages a unique combination of three alpha hydroxy acids (AHAs) that may help improve the appearance of skin surface and textur
- Merz’s Xeomin Taps Teyana Taylor as Brand Partnerhttps://practicaldermatology.com/news/merzs-xeomin-taps-teyana-taylor-as-brand-partner/2461412/Teyana Taylor is the latest brand partner for Merz’z Xeomin (incobotulinumtoxinA). The U.S. partnership is a continuation of the ‘Beauty on Your Terms’ campaign for Xeomin, an FDA-approved double filtered anti-wrinkle injection to temporarily improve the appearanc
- Happy 30th Birthday NRS!https://practicaldermatology.com/news/happy-30th-birthday-nrs/2461410/The National Rosacea Society (NRS) is celebrating its 30th anniversary in 2022. The past three decades have seen tremendous progress toward fulfilling our mission of improving the lives of people with rosacea through awareness, education and support of medical research.
- EWG: FDA Must Ban Oxybenzone in Sunscreen Now!https://practicaldermatology.com/news/ewg-fda-must-ban-oxybenzone-in-sunscreen-now/2461405/The U.S. Food and Drug Administration (FDA) should ban oxybenzone in sunscreens, according to researchers at the Environmental Working Group (EWG). For decades, sunscreen makers have used oxybenzone in their products, despite concerns about its health harms. In 2021, the FDA t
- Nevisense Improves Dermatologist’s Decision-making Beyond Dermoscopyhttps://practicaldermatology.com/news/nevisense-improves-dermatologists-decision-making-beyond-dermoscopy/2461403/SciBase’s Nevisense test provides benefit over standard of care visual and dermoscopic evaluation for biopsy decisions, according to a study in Melano